Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice
Benson Chellakkan Selvanesan, Kiran Meena, Amanda Beck, Lydie Meheus, Olaya Lara, Ilse Rooman, Claudia Gravekamp. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. Journal for Immunotherapy for Cancer, 2020;8:e001250, doi:10.1136/jitc-2020-001250
Pancreatic cancer, more specifically its common aggressive form, pancreatic ductal adenocarcinoma, has very little therapeutic options.
Because of sparse evidence in literature, we tested nicotinamide (vitamine B3) as an add-on to a treatment with gemcitabine in mouse models of pancreatic cancer. This combination therapy was effective in reducing tumor growth and metastasis by activating anti-tumor immunity and by modulating the stroma.
The study warrants further exploring the potential of nicotinamide plus gemcitabine as immunotherapy in pancreatic cancer.
Read the full article here.